Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "volatile sulfur compound–producing oral bacteria" refers to a diverse group of primarily anaerobic, gram-negative bacteria that reside in the oral cavity and generate volatile sulfur compounds (VSCs)—notably hydrogen sulfide, methyl mercaptan, and dimethyl sulfide—through the degradation of sulfur-containing amino acids during protein metabolism[1][3][4][5][7][8][9]. Major genera and species include Porphyromonas (e.g., *P. gingivalis*, *P. endodontalis*), Prevotella (*P. intermedia*), Fusobacterium (*F. nucleatum*), Bacteroides, Eubacterium, Selenomonas, Veillonella, Peptostreptococcus, and Treponema[1][3][5][8]. These bacteria are strongly implicated as causative agents in halitosis (oral malodor) and play a role in the pathogenesis of periodontal diseases through their cytotoxic metabolites and promotion of local inflammation, tissue destruction, and possible systemic effects[1][4][5][7]. This is not a molecular target as defined by drug discovery convention (e.g., a receptor, enzyme, transporter, or well-characterized protein), but rather a large and diverse ecological group of bacteria sharing a functional trait. Accordingly, it does not map to an individual canonical gene, protein, or validated drug target. Additional Notes: These bacteria produce VSCs mainly when degrading substrates like L-cysteine and L-methionine found in the oral cavity[1][5][8]. Current interventions target the microbial community or VSCs themselves, not a specific molecular target[3]. Hydrogen sulfide in particular may serve as a biomarker for monitoring disease progression or response to therapy[5]. Summary: "Volatile sulfur compound–producing oral bacteria" is not a canonical therapeutic target but describes a functional group of oral microorganisms responsible for VSC-mediated oral malodor and frequently associated with periodontal pathology[1][3][5][9].
Antimicrobial and chemical inhibition of sulfur compound formation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Volatile sulfur compound–producing oral bacteria.